{"id":"W4401379890","doi":"10.1200/jco.2024.42.4_suppl.18","title":"CONTACT-02: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; Centre Hospitalier de l’Université de Montréal","funders":"Exelixis","keywords":"Medicine; Docetaxel; Clinical endpoint; Internal medicine; Prostate cancer; Oncology; Hormonal therapy; Metastatic breast cancer; Enzalutamide; Androgen deprivation therapy; Taxane; Urology; Cancer; Randomized controlled trial; Breast cancer; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001600656,0.0002196718,0.00160173,0.0003051588,0.00004042489,0.00002727497,0.0001462585,0.000134453,0.0003273815],"category_scores_gemma":[0.0002219168,0.0001256877,0.0002180484,0.0003648818,0.0001846256,0.0002212149,0.00002950635,0.0009951693,0.000003560005],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004272498,"about_ca_system_score_gemma":0.005881177,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002757224,"about_ca_topic_score_gemma":0.001151186,"domain_scores_codex":[0.996034,0.0003045783,0.00225536,0.0003070463,0.0007579376,0.0003411091],"domain_scores_gemma":[0.9969071,0.0009841918,0.0009208896,0.0001700578,0.0007185067,0.0002992326],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.4442075,0.05987224,0.2547798,0.0005744766,0.007367562,0.008842922,0.008247887,0.0001530617,0.00429293,0.0001025196,0.002056849,0.2095022],"study_design_scores_gemma":[0.2168133,0.2098989,0.5588843,0.0005766005,0.0006385199,0.0001010176,0.001678881,0.0003877585,0.0004954746,0.00003874375,0.01027922,0.0002073169],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945292,0.002001863,0.000009700291,0.001222575,0.0005227756,0.00129029,0.00009592806,0.000007684656,0.0003199909],"genre_scores_gemma":[0.9977053,0.001078747,0.0002740832,0.0001987134,0.0001773569,0.00004831898,0.00001522496,0.00002931789,0.0004729791],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3041044,"threshold_uncertainty_score":0.9997545,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1526407257271968,"score_gpt":0.5031225171413383,"score_spread":0.3504817914141414,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}